Clinical Trial Detail

NCT ID NCT02523469
Title ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors John Wrangle
Indications

lung non-small cell carcinoma

Therapies

ALT-803 + Nivolumab

Age Groups: adult

No variant requirements are available.